Management will participate in TD Cowen’s 44th Annual Health Care Conference, Leerink Partners 2024 Global Biopharma Conference, and Stifel’s 2024 Virtual CNS Days. Learn more: bwnews.pr/3T5dbR0

Today, we announced several exciting updates to our Phase 1/2 trial of NGN-401 in female pediatric patients with Rett syndrome, which are designed to expand the trial, accelerate enrollment, and inform potential future registrational studies: bit.ly/4bXffmx

Today, we reported fourth quarter and full year 2023 financial results and highlighted recent updates. For full details and results, read today’s press release: bit.ly/3IFNNfw

Going to ASGCT this year? We look forward to sharing preliminary safety results from our ongoing Phase 1/2 study of NGN-401 in female pediatric patients with Rett syndrome. Read today’s press release to learn more: bit.ly/49NOKO3 #ASGCT2024

Today we announced favorable safety data from our ongoing Phase 1/2 trial of NGN-401 in female pediatric patients with Rett syndrome, which will be presented at ASGCT on May 9. Read today’s press release to learn more: bit.ly/3UvXQcH #ASGCT2024

Today, we reported first quarter 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: bit.ly/4bh1Uon

We are excited to announce that NGN-401 gene therapy for Rett syndrome was one of only three CBER programs selected for inclusion in the FDA’s START Pilot Program, which is designed to accelerate the development of therapies for rare diseases. Learn more: bit.ly/3V7DLdd

During June, Neurogene will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, the 2024 IRSF Rett Syndrome Scientific Meeting, and the TD Cowen Genetic Medicines & RNA Summit. Learn more: bit.ly/4bJU3Qh

We had the pleasure of hosting college students at our gene therapy manufacturing facility via #NIIMBLeXperience, a program offering students from traditionally underrepresented populations the chance to gain real-world insight into biopharma. Learn more: bit.ly/3Ky6mDr

Tune in today at 1:20 p.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, present at the Goldman Sachs 45thAnnual Global Healthcare Conference. A link to the webcast is available here: bit.ly/4bSuYD8

We are pleased to share the first patient was dosed in the high-dose cohort of NGN-401 gene therapy trial for #Rettsyndrome and has been well-tolerated thus far. We'll share updated interim safety data from the low-dose cohort International Rett Syndrome Foundation ASCEND Summit. bit.ly/3XsvGST

Tune in today at 10:40 a.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit. A link to the webcast is available here: bit.ly/4c8pYKe

Today, we joined the Russell 3000® Index as part of FTSE Russell, An LSEG Business #RussellRecon. Learn more here: bit.ly/4eMgh69

On Tuesday, July 9, management will participate in the BMO 2024 Genetic Medicines Summit. Learn more: bit.ly/3L68OBx

Thank you Nasdaq Exchange for hosting us for an amazing morning ringing today’s opening bell! Watch the ceremony here: bit.ly/4dufaXu $NGNE #NasdaqListed

🥼 Neurogene Inc is on a mission to improve the lives of patients and families devastated by rare neurological diseases. 🧬 The medicine Neurogene Inc. is creating has the potential to change the way these disorders are treated. 🔔 Proud to be your partner $NGNE! #NasdaqListed

We are excited to announce that the U.S. FDA has granted Regenerative Medicine Advanced Therapy #RMAT designation to NGN-401 for #RettSyndrome. Learn more: bit.ly/3T2HyZ9

Today, we reported second quarter 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: bit.ly/3YELJ0O

Tune in today at 11:00 a.m. ET to watch our Founder and Chief Executive Officer, Dr. Rachel McMinn, in a fireside chat at the H.C. Wainwright & Co. 26th Annual Global Investment Conference. A link to the webcast is available here: bit.ly/4dWYFDE #HCWainwrightGlobal

Tune in today at 2:30 p.m. ET to watch our Founder and Chief Executive Officer, Dr. Rachel McMinn, in a fireside chat at the Cantor Global Healthcare Conference. A link to the webcast is available here: bit.ly/4g3hTsT #CantorHCC